A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
546actual
Sites
70
Countries
Brazil, China, Japan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-10 | actual | When the study began enrolling |
| Primary completion | 2025-09-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-15 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Interventions
- Drug: Orforglipron — also filed as LY3502970
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFOrforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)
measured Baseline, Week 40
Publications
- PMID 42251769 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed